Skip to content
Insight

FUJIFILM invests more than 900 mio. USD in expanding its biologics production facility in Denmark

With FUJIFILM’s new major capital investment of approximately 100 billion yen (928 million USD) in the Danish site of FUJIFILM Diosynth Biotechnologies, the life science sector in Denmark once again proves to be capable of attracting significant foreign investments and the Danish life science ecosystem is becoming even stronger and competitive.
When 11.06.2020
What
Life Sciences Pharma & Biotech
A few weeks after announcing a number of new export- and investment promotion initiatives in the wake of the covid-19 crisis, Denmark is now attracting one of the largest foreign investments into Denmark ever recorded.

With its new capital investment FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies, will double the current drug substance manufacturing capacity in their facilities in Hillerød in Denmark, and will expand its capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.

The investment also means that the site will become one of the few major largescale manufacturing facilities in the global bio-CDMO industry and become a flagship facility for FUJIFILM Diosynth Biotechnologies.
quote ikon
“Since the acquisition of the site last year, the facility's strong manufacturing track-record, coupled with FUJIFILM Diosynth Biotechnologies' technologies enabling a stable supply of high-quality biopharmaceuticals, has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion.”
Mr. Ishikawa, Director Executive Vice President from FUJIFILM Corporation
FUJIFILM Diosynth Biotechnologies acquired the site in Denmark from the American company Biogen in August last year. In April 2020, FUJIFILM Diosynth Biotechnologies announced that it will reserve manufacturing capacity for a future COVID-19 therapy for the COVID-19 Therapeutics Accelerator - an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic.
quote ikon
“Foreign companies investing in Denmark are an important part of Denmark’s business community. Recently, the Danish government launched a new strategy for attracting sustainable foreign investments contributing to the government’s ambition of pursuing an active business policy. The life science sector is a key focus area in the strategy as Denmark besides a stable business environment offers international life science companies an innovative environment, high productivity, sustainable production and a green profile. This milestone investment by FUJIFILM Diosynth Biotechnologies is a testament to that fact.”
Jeppe Kofod Minister for Foreign Affairs

About Fujifilm Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonalantibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation.

For more information go to www.fujifilmdiosynth.com.


Do you want to know more about biotech in Denmark?

Please contact our dedicated advisors here:

Loading...